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Rap1 regulates hematopoietic stem cell survival and
affects oncogenesis and response to chemotherapy
Ekta Khattar1,9, Kyaw Ze Ya Maung1,9, Chen Li Chew1,9, Arkasubhra Ghosh 1,9, Michelle Meng Huang Mok 2,
Pei Lee3, Jun Zhang4, Wei Hong Jeff Chor1, Gökhan Cildir 1,3, Chelsia Qiuxia Wang1,
Nur Khairiah Mohd-Ismail1, Desmond Wai Loon Chin2, Soo Chin Lee2, Henry Yang2, Yong-Jae Shin5,
Do-Hyun Nam5, Liming Chen4, Alan Prem Kumar 2, Lih Wen Deng 3, Masahito Ikawa 6,7,
Jayantha Gunaratne1, Motomi Osato2 & Vinay Tergaonkar1,8*
Increased levels and non-telomeric roles have been reported for shelterin proteins, including
RAP1 in cancers. Herein using Rap1 null mice, we provide the genetic evidence that mam-
malian Rap1 plays a major role in hematopoietic stem cell survival, oncogenesis and response
to chemotherapy. Strikingly, this function of RAP1 is independent of its association with the
telomere or with its known partner TRF2. We show that RAP1 interacts with many members
of the DNA damage response (DDR) pathway. RAP1 depleted cells show reduced interaction
between XRCC4/DNA Ligase IV and DNA-PK, and are impaired in DNA Ligase IV recruit-
ment to damaged chromatin for efficient repair. Consistent with its role in DNA damage
repair, RAP1 loss decreases double-strand break repair via NHEJ in vivo, and consequently
reduces B cell class switch recombination. Finally, we discover that RAP1 levels are predictive
of the success of chemotherapy in breast and colon cancer.
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RAP1 (also known as TERF2IP) is a member of the shelterincomplex that associates with and protects mammaliantelomeres1,2. This complex is composed of five other core
members, namely TRF1, TRF2, TIN2, POT1, and TPP1, and it is
also important for regulating telomerase recruitment3. Human
RAP1 was identified as a TRF2-interacting protein that is an
ortholog of the yeast telomeric protein Rap1p4. Multiple roles
have been described for yeast Rap1p both at the telomere and at
other sites on the chromatin, including telomere length regula-
tion, transcriptional activation, heterochromatin boundary-
element formation, and subtelomeric silencing through recruit-
ment of the Sir complex3. Human RAP1 differs from its yeast
counterpart in that it is unable to directly bind telomeric DNA
and it requires interaction with TRF2 for recruitment to the tel-
omeres4. There is recent evidence suggesting that human RAP1
may interact directly with DNA in a sequence-independent
manner5. Similar to yeast Rap1p, mammalian Rap1 has been
suggested to play a role in telomere length maintenance6,7.
However, recent studies have revealed that mammalian Rap1 is
dispensable for telomere capping, indicating that Rap1 may
instead protect telomeres indirectly through the regulation of
DNA repair activities at telomere ends8–12. Sfeir et al.9 reported
that the conditional loss of Rap1 alone did not affect telomere
length, induce the formation of telomere dysfunction-induced
foci (TIFs) or promote telomeric fusions. The roles of mamma-
lian Rap1 are only beginning to be clearly understood.
Since increased levels of RAP1 and other telomeric proteins are
seen in many human malignancies, understanding their telomeric
and non-telomeric roles has gained momentum3,13–18. Non-
canonical roles were first described for TRF2 and TIN2 at non-
telomeric DNA double-strand breaks (DSB) and heterochromatin
protein 1γ-marked extra-telomeric sites, respectively19,20. Recently,
using genome-wide chromatin immunoprecipitation-sequencing
(ChIP-seq), RAP1 was shown to regulate gene transcription12.
Additionally, TPP1, RAP1, POT1, and TIN2 were shown to be
present in non-chromatin-bound cellular fractions, suggesting a
broader role for these proteins away from the telomeres13,21. In an
unbiased screen for regulators of nuclear factor κB (NFκB), we
reported that RAP1 promotes NFκB-dependent inflammatory gene
expression22. Our results demonstrates a telomere-independent,
cytoplasmic role for mammalian Rap1. Rap1 has also previously
been shown to have extra-telomeric functions in transcriptional
regulation of metabolic pathways23,24. However, the possible roles
of RAP1 in regulating signaling pathways which influence cancer
initation, progression, or treatment are largely unknown.
There have been reports of interactions between RAP1 and
members of the DNA damage response (DDR) pathway7,25. How-
ever, the functional significance of these interactions remains to be
elucidated. Considering the well-established role of DDR in genome
stability and cancer prevention, investigation into the role of RAP1 in
the context of DNA repair and tumorigenesis is an important
unexplored area. In this report we uncover that mammalian Rap1
interacts with several DNA repair proteins independent of TRF2 and
functions as an adapter for key proteins which mediate repair in
response to DNA damage initated by genotoxic agents and onco-
genes. Most notably, the importance for the role of RAP1 in DDR is
provided by data from human clinical trials which shows that RAP1
levels correlate with the success of chemotherapy for breast and
colon cancer using DNA damaging agents. Overall, these findings
have implications for initiation, progression and treatment of cancer.
Results
Rap1-deficient mice do not display gross abnormalities. In
order to genetically evaluate the role of Rap1 in mammals, we
generated Rap1 conditional knockout mice. Exon 2 of Rap1
flanked by loxP sites was inserted into the Rap1 locus (Supple-
mentary Fig. 1A). To generate whole-body Rap1 knockout mice
(KO, Rap1−/−), chimeric mice inheriting this recombinant Rap1
allele were crossed to β-actin-Cre transgenic mice26. Mouse
embryonic fibroblasts (MEFs) derived from E13.5 embryos con-
firmed the loss of Rap1 protein and mRNA expression in
knockout cells (Supplementary Fig. 1B). Rap1 KO mice were born
at normal Mendelian frequencies, were fertile, and showed no
overt pathologies at birth. As previously reported, Rap1 null mice
were obese and this phenotype was particularly evident in
females23,24.
Bone marrow (BM) failure is a characteristic feature of several
diseases known to be associated with telomere dysfunction27. To
test the role of Rap1 in BM homeostasis in mice, we evaluated the
status of different hematopoietic cells with or without Rap1 at
steady-state. Hematological parameters such as white blood cells,
hemoglobin, and platelet counts between Rap1 wild type (WT)
and KO mice (Supplementary Fig. 1C) did not reveal any
significant differences. The percentage of myeloid progenitors (c-
Kit+ Sca-1- Lin-, KL, where c-Kit+ denotes c-Kit-positive cells,
Sca-1− denotes Sca-1-negative cells) and Hematopoietic Stem and
Progenitor Cells (HSPC, c-Kit+ Sca-1+ Lin−, KSL) in the BM
were similar in both Rap1 WT and KO mice (Supplementary
Fig. 1D, E). Furthermore, populations of myeloid and erythroid
cells in the BM and T cells and B cells in the spleen were
comparable between Rap1 KO mice and WT controls (Supple-
mentary Fig. 1F). A detailed analysis of the T cells and B cells at
various stages of development and maturity show no significant
differences between Rap1 WT and Rap1 KO mice (Supplemen-
tary Fig. 1G, H). Thus, under homeostasis, the loss of Rap1
expression does not have any significant effects on the different
hematopoietic cell populations in the BM and spleen.
Loss of Rap1 sensitizes mice to DNA damaging agents. To
evaluate if Rap1 is involved in celluar stress response in vivo, we
challenged littermate Rap1WT and KO mice with a lethal dose of
(11 Gy) whole-body irradiation that causes DNA DSBs. Rap1 KO
mice were significantly more susceptible to irradiation and died
within 4–8 days while WT controls survived longer (Fig. 1a). Loss
of Rap1 also sensitized mice to DSB caused by chemotherapeutic
agent 5-Fluorouracil (5-FU) (Supplementary Fig. 2A). Since BM
is one of the most affected tissue compartments against DSB
inducers, we next analyzed cellular changes in this compartment.
We first checked the HSPC and myeloid progenitors in BM of
mice subjected to a sublethal dose of irradiation (5 Gy) for defects
in cellularity. An acute reduction in the KL and KSL cell popu-
lations was observed in Rap1 KO mice compared to WT controls
at 24 h and 2 weeks after irradiation (Fig. 1b, quantified in
Fig. 1c). It is worth noting that there was no difference in the cell
cycle profile of Rap1 WT and Rap1 KO mice (Fig. 1d). Annexin
V/propidium iodide (PI)-staining apoptosis assay revealed a sig-
nificant increase in cell death (upon 5 Gy treatment) in the Rap1
KO mice compared to the Rap1 WT mice (Fig. 1e). This suggests
that loss of Rap1 rendered these cells unable to recover from
radiation-induced damage due to enhanced apoptosis. To further
test this notion, we analyzed the colony-forming potential of total
BM cells from 5 Gy irradiated Rap1 WT and KO mice. Rap1-
deficient cells formed fewer colonies on methylcellulose plates
compared to WT controls in the replating (Fig. 1f). This differ-
ence was further amplified when cells from the primary plate
were replated (Fig. 1g). Taken together, these data suggest that
the enhanced sensitivity of Rap1 KO mice to genotoxic agents
could be a consequence of BM failure in these mice due to the
inability of Rap1 null HSPCs to proliferate and repopulate after
irradiation.
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Rap1 null HSPCs accumulate more DNA damage after irra-
diation. To determine if the observed difference in irradiation
sensitivity in these mice is due to defects in DNA damage repair,
we performed intracellular flow cytometry staining and immu-
nofluorescence analysis for phosphorylated H2AX (γ-H2AX), a
marker for DNA damage, on HSPCs from irradiated mice.
Within the cKit+lin− cell population, there was a higher per-
centage of γ-H2AX-positive cells 1 h after irradiation in Rap1 KO
mice compared to the WT controls (Fig. 2a, b). Furthermore,
while Rap1WT cells were able to resolve the DNA damage within
2 weeks post-irradiation, the γ-H2AX foci persisted in the cells
from Rap1 KO mice (Fig. 2c, d). Therefore, the increased

































Rap1 G1 S G2M
Untreated
WT 79.1% 11.4% 12.8%
KO 78.1% 12.0% 11.6%
5-Gy
24 h
WT 75.9% 10.9% 12.6%
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Fig. 1 Loss of Rap1 sensitizes mice to γ-irradiation and 5-FU. a Survival curve for Rap1WT and KOmice treated with 11 Gy γ-irradiation (n= 5/genotype). b Flow
cytometric analysis of HSPC compartment in bone marrow (BM) of 6- to 8-week-old mice 24 h and 14 days after a single dose of 5 Gy irradiation.
Representative FACS plots of 200,000 cells gated on viable Lin- cells are shown. Percentages in parent gate are shown. c Graphical representation of the results
presented in b is shown. Mean ± SEM of the percentage of KSL (right) and KL (left) within the BM Lin− (Lin1 negative) population. * represents p < 0.05 (two-
tailed Student’s t-test). Number of mice for each genotype used (n= 7) (data points for 2 Rap1 WT and 3 Rap1 KO mice were not included in Day 14 analyses
because they died before the time point). d Cell cycle analysis with PI staining of the haematopoietic progenitor cells (KLS cells) and table summarizing the
percentage of cells in G1, S, and G2M phases across the different genotypes. Number of mice for each genotype used (n= 3). e Annexin/PI staining of
haematopoietic precursor (KLS cells) with/without 5 Gy irradiation and recovered for 24 h. Leftmost column depicts the gating of KLS cell populations. The
rightmost panels depict the Annexin V (X-axis) and PI (Y-axis) analysis of KLS cells. Number of mice for each genotype used (n= 3). f Pictures of
representative plates in the replatings are shown. Scale bar, 10mm. g Colony-forming potential of total BM cells after irradiation. Colonies with more than 20
cells were scored from triplicate samples. Mean ± SEM of triplicate samples from n= 2/genotype is depicted. ***p < 0.001 (Mann–Whitney U-test).
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Fig. 2 Loss of Rap1 leads to genomic instability. a Flow cytometric analysis of the γ-H2AX. Representative FACS plots of 30,000 gated cells on viable c-Kit
+Lin− (c-Kit positive, Lin1 negative) cells are shown. b Graphical representation of the results presented in a is shown. Mean ± SEM of the percentage of
γ-H2AX-positive cells in the c-Kit+Lin- fraction. Results represented are from two independent experiments (n= 6/genotype). * represents p < 0.05 (two-
tailed Student’s t-test). c Representative images of the γ-H2AX staining in c-Kit+Lin−-derived cells using immunofluorescence staining. Scale bar, 10 μm.
d Graphical representation of the γ-H2AX-foci numbers on 1 h and 14 days after irradiation, respectively. Results of γ-H2AX-foci scoring at 1 h (left) and
14 days (right) after 5 Gy irradiation are shown. Mean ± SD of duplicate experiments is depicted. *p < 0.05 (Mann–Whitney U-test).
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sensitivity to irradiation observed in Rap1 KO mice may be due,
in part, to the inability of cells to heal the DNA damage effec-
tively. Unresolved γ-H2AX foci in BM cells of Rap1 KO mice
were also observed in response to 5-FU injection (Supplementary
Fig. 2B, C). To further demonstrate the increased sensitivity of the
Rap1 KO cells to genotoxic stress, comet assay was performed in
Rap1 WT and Rap1 KO MEFs, and incresaed DNA fragmenta-
tion is observed in Rap1 KO MEFs (Supplementary Fig. 2D, E).
Taken together, these show that Rap1 loss impairs the ability of
cells to resolve DNA damage.
Rap1 loss accelerates tumorigenesis in Eµ-Myc mice. Intact
DDR signaling plays a crucial role in preventing oncogene-driven
tumorigenesis28,29. To determine if Rap1-mediated regulation of
DDR contributes to this process, we crossed Rap1 KO mice with
Eµ-Myc transgenic mice30, where B cell-specific overexpression of
the Myc oncogene leads to lymphomas. Since overexpression of
Myc has been shown to induce DNA damage31–33, accelerated
tumorigenesis is expected with defects in DDR signaling. Indeed,
in the absence of Rap1, lymphomagenesis was significantly
accelerated, resulting in poorer overall survival and greatly
increased tumor burden for Eμ-Myc mice in Rap1 null back-
ground compared to littermate Eμ-Myc Rap1 WT controls
(Fig. 3a). Eµ-Myc Rap1 KO mice developed bigger tumors and
had severely enlarged spleens and lymph nodes (LN) (Fig. 3b, c).
Similarly, increased tumor sizes (and accelerated tumorigenesis)
were observed in PyMT mice in Rap1 null background, compared
to littermate PyMT controls (Supplementary Fig. 2F). B cell
populations (B220+, where B220+ denotes B220-positive cells) in
the BM, spleen, and LN of Eμ-Myc Rap1 KO mice were sig-
nificantly increased (Fig. 3d). In line with this, immunohis-
tochemistry analysis of LN and spleen sections revealed higher
levels of cell proliferation in Eµ-Myc Rap1 KO mice, as evidenced
by more intense Ki67 staining (Fig. 3e). Moreover, increased γ-
H2AX staining was observed in splenic B cells in Eμ-Myc Rap1
KO mice (Fig. 3f) suggesting that Rap1 delays disease progression
in Myc-induced lymphomagenesis, possibly by regulating Myc-
induced damage. Given that we see effects in Myc-driven and
PyMT-driven cancers, it is likely that Rap1 plays a role in other
types of stem cells.
Rap1 is required for cell survival upon genotoxic challenge.
Similar to irradiation and 5-FU accelerated death in Rap1 KO
mice, camptothecin (CPT) treatment also increased cell death in
Rap1 KO MEFs (n= 2) compared to WT MEFs (n= 2) and
increased γ-H2AX accumulation (Fig. 4a, b). We extended these
findings to human cells which are biochemically more tractable
for further analysis. Similar results were obtained in human
MCF7 cells in response to CPT, Doxorubicin (DOX) (Fig. 4c, d),
Etoposide, and Mitomycin-C (Supplementary Fig. 2G, H) upon
RAP1 knockdown. As a positive control, DNA-PK knockdown
also showed enhanced cell death upon CPT treatment (Supple-
mentary Fig. 2I). DSBs are known to also activate NFκB signaling
which protects cells from death34,35. Given that RAP1 activates
NFκB signaling in response to cytokines22, we tested whether
NFκB activation by genotoxic agents, which is initiated in the
nucleus, is also regulated by RAP1. Knockdown of RAP1 did not
affect NFκB DNA binding upon treatment with Dox or CPT
(Supplementary Fig. 2J), therefore, excluding the possibility that
increased sensitivity to DSB inducers in the absence of RAP1 is
due to decreased NFκB activation. This suggests that RAP1’s
function in DNA damage could be independent of its role in
transcription.
To test the level of damage upon RAP1 knockdown in human
cells, we compared the level of DNA damage in RAP1 knockdown
and control cells using γ-H2AX as a marker. Knockdown of
RAP1 using short-hairpin RNAs (shRNA) did not result in off-
target effects on the shelterin complex or key NFκB signaling
proteins (Supplementary Fig. 3A, B). Loss of RAP1 also caused
increased accumulation of γ-H2AX upon CPT treatment in
human cells (Fig. 4e). We also observed more γ-H2AX foci
(Fig. 4f, g), colocalized with 53BP1 (Supplementary Fig. 3C),
another marker of DNA damage. The quantification is presented
in Supplementary Fig. 3D. Depletion of RAP1 does not induce
significant TIFs (Supplementary Fig. 3E) as shown before24. To
understand whether the damage foci preferentially reside on
telomeres following CPT treatment, we costained γ-H2AX with
TTAGGG-PNA probe and observed that damage foci were not
specific to telomeres (Supplementary Fig. 3F). We confirmed that
PNA probe specifically stained the telomeres (Supplementary
Fig. 3F). These results show that RAP1-depleted cells accumulate
more damage which is not limited to the telomeric regions, and
that they concomitantly show more cell death.
RAP1 binds to proteins involved in DNA damage repair. To
identify possible RAP1 interactions with proteins that regulate
DDR, we performed stable isotope labeling of amino acids in cell
culture followed by mass spectrometry (SILAC-MS) using Flag-
RAP1-expressing 293T cells (Supplementary Fig. 4A). Proteins
with high SILAC ratios (>3) were then subjected to pathway
analysis using GeneGO (MetaCoreTM, version 6.11). A ratio-
intensity plot of the RAP1-interacting proteins showed that RAP1
associates with several important members of the DDR pathway,
including DNA-PK, Ku80, Ku70, Rad50, and MRE11 (Supple-
mentary Fig. 4B). Indeed, among the RAP1-interacting proteome,
the DDR pathway proteins were highly enriched (Supplementary
Fig. 4C) (p < e-22). We further confirmed the interactions
between endogenous RAP1 and DDR pathway members using
size exclusion chromatography22 and endogenous RAP1 IP. We
find that RAP1 interacts with many DDR proteins such as DNA-
PK, DNA Ligase IV (Ligase IV), and ATM in untreated cells
(Supplementary Fig. 4D). More importantly, the size of these
complexes increased upon treatment with genotoxic drugs, Dox
and CPT (compare lane numbers 1 vs. 7 and 13 in IP: RAP1 gel)
(Supplementary Fig. 4D). This indicates that RAP1 may be a part
of large functional complexes that regulate DDR upon genotoxic
stress. Association of RAP1 with some DDR pathway members
suggests that RAP1 may function as an adapter protein required
for efficient signaling of the DDR pathway, which is reminiscent
of its role in the canonical IKK signaling pathway22. To identify
the domains of RAP1 required for binding to the various DDR
proteins, we used Flag-tagged RAP1 mutants which have been
previously reported6. Interestingly, RAP1 binds to different pro-
teins via different domains (Supplementary Fig. 4E). RAP1
mutants lacking the CT or M/C domains were unable to bind to
DNA-PK while TRF2 required the CT domain for binding. This
suggests that while RAP1 may use different domains for binding
different proteins, the CT domain appears to be the most
important for interaction with multiple proteins. Since CT
domain was required for binding with TRF2 as well as DDR
proteins, we checked if RAP1-DDR protein interactions are TRF2
dependent. To this end, we made six amino acid linker scanning
mutations in CT domain of RAP1 between residues 325 and 330
(named as RAP1–325). Consistent with previous findings that
amino acid residues around 318 are necessary for TRF2 binding
to human RAP1 (ref. 36), we observed that RAP1–325 was unable
to bind to TRF2 (Fig. 5a). Importantly, RAP1–325 was able to
bind to DDR proteins like DNA-PK, XRCC4, and Ligase IV
(Fig. 5a), suggesting that its interactions with these DDR mem-
bers are independent of TRF2.
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Fig. 3 Myc-induced lymphomagenesis is accelerated in the absence of Rap1. a Kaplan–Meier survival curve of Eμ-Myc Rap1 WT (n= 12) and KO (n= 16)
mice. *p value <0.05. Samples were collected after 15 weeks. b Photographs of a representative pair of Eμ-Myc Rap1 WT and KO mice with enlarged LN
(scale bar, 2 cm). Photos shown below are representative of spleen and LN. Samples were collected after 15 weeks. c Weights of spleen and different LN
from Eμ-Myc Rap1 WT and KO mice are plotted (n= 4). d Percentage of B cells (B220+) derived from the bone marrow, spleen, and LN of Eμ-Myc Rap1
WT and KO mice as determined by flow cytometry (n= 2/genotype). Mean ± SD of the percentage of B220+ (B220 positive) cells is depicted. Samples
were collected after 15 weeks. *p < 0.05 (Mann–Whitney U-test). e Immunohistochemical Ki67 staining of Eμ-Myc Rap1 WT and KO LN and spleen
sections. Samples were collected after 15 weeks. Scale bar, 100 μm. f Intracellular γ-H2AX staining of B cells from spleen of Eμ-Myc Rap1 WT and KO.
Gated cells indicate percentage of γ-H2AX-positive cells. Samples were collected after 15 weeks.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13082-9
6 NATURE COMMUNICATIONS |         (2019) 10:5349 | https://doi.org/10.1038/s41467-019-13082-9 | www.nature.com/naturecommunications
RAP1 mediates XRCC4/Ligase IV and DNA-PK interaction.
To understand the role of RAP1 in DDR, we evaluated the
kinetics of recruitment of these proteins on chromatin in cells
treated with CPT and subsequently released for repair. Strikingly,
the recruitment of Ligase IV to chromatin was impaired when
RAP1 was depleted (Fig. 5b). Interestingly, association of DNA-
PK and pATM with damaged chromatin was increased when
RAP1 was depleted, possibly due to persistent unresolved breaks
(Fig. 5b). This data suggested that RAP1 may be functioning as a
platform that helps to recruit different complexes for efficient
repair. To further characterize the function of RAP1, we analyzed
the formation of DNA repair complexes prior to their association
with chromatin by co-immunoprecipitation. While XRCC4
associated with DNA-PK, an association required for efficient
repair in response to DNA damage, this interaction was markedly
reduced in the absence of RAP1 (Fig. 5c). However, the asso-
ciation between Ligase IV and XRCC4 was unaffected by levels of
RAP1. Further, a reverse IP demonstrated that DNA-PK inter-
action with Ligase IV/XRCC4 was markedly diminished in the
absence of RAP1 (Fig. 5c). These experiments support the
hypothesis that RAP1 interacts with DNA repair proteins
XRCC4/Ligase IV and DNA-PK to promote DNA damage repair.
Rap1 affects key NHEJ processes in vivo. Given that our assays
reveal a role for RAP1 in DNA damage repair, we next aimed to
strengthen this claim by directly testing RAP1’s function in DDR
using physiological in vivo assays. Consistent with the impaired
recruitment of Ligase IV, the DSB repair activity in RAP1-
depleted cells was lower compared to control cells. A cell-based
double vector system previously described by Bennardo et al.37
was used to probe the efficiency of NHEJ in RAP1-depleted cells
(Fig. 6a). Control and RAP1 knockdown MCF7 cells were tran-
siently transfected and the repair efficacy was measured using
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Fig. 4 Rap1 promotes cell survival and DNA damage repair after chemotherapeutic drug treatment. a Rap1 WT and KO MEFs were treated with various
doses of CPT and analyzed for cell death after 48 h. Mean ± SD of duplicate experiments are presented. *p < 0.05 (two-tailed Student’s t-test). b Western
blot analysis in Rap1 KO and WT MEFs upon CPT treatment for indicated time points. c, d MCF7 cells were transfected with RAP1 or scrambled control
siRNAs and cell survival was measured after 48 h treatment with CPT (60 μM) or Dox (1 μM) as indicated. Mean ± SD of the percentage cell death in
duplicate experiments is depicted. *p < 0.05 (two-tailed Student’s t-test). e Western blot analysis in shControl and shRAP1-transfected MCF7 cells and
released for different time points after CPT (10 μM, 3 h) treatment. f Immunofluorescence staining of γ-H2AX after CPT treatment (10 μM, 3 h) in RAP1
knockdown and control MCF7 cells (×60 magnification). Scale bar, 20 μm. g Quantification of f. Mean ± SEM of three separate fields is depicted. Each
experiment was repeated three times and *p < 0.05 (two-tailed Student’s t-test).
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NHEJ repair activity in the RAP1 KD cells compared to the
control cells (Fig. 6b, c), supporting the role for RAP1 as an
adaptor protein in NHEJ DNA repair.
Next, we wanted to analyze the effect of Rap1 deficiency on B
cell class switching, a physiologically relevant process where
NHEJ repair plays an important role38–40. Splenic B cells isolated
from WT and Rap1 KO mice were stimulated with LPS and IL-4
cytokines to undergo IgG1 class switching. B cells isolated from
Rap1 KO mice displayed significantly reduced IgG1 class
switching (representative FACs plots and quantification: Fig. 6d,
e; percentage decrease normalized to WT over three experiments:
Fig. 6f; averaged over three experiments: Fig. 6g). Together, these
experiments provide in vivo evidence that Rap1 deficiency affects
physiologically relevant processes where NHEJ mediated repair
plays an important and non-redundant role. Taken together, this
reinforces our hypothesis that despite not being a cannonical
member of the NHEJ repair pathway, RAP1 enhances NHEJ
activity by working as a potential adaptor in specific contexts.
RAP1 levels predict chemotherapy response and survival. To
further investigate the relevance of our findings in human cancer
patients, tissue microarray (TMA) blocks containing serial tumor
cores from 100 breast cancer patients were constructed as
described previously41. As a result of tissue loss during TMA
construction and immunohistochemical processing, the following
number of cases were available for evaluation: ER-negative
patients, n= 17 and ER-positive patients, n= 31. We used ER-
positive patient samples for IHC with RAP1. RAP1 staining on
TMA blocks containing serial tumor cores were graded according
to the intensity into four groups: 0 (negative), 1 (weak), 2
(moderate), and 3 (strong). Staining scores 0 and 1 were grouped
as negative immunoreactivity whereas 2 and 3 were grouped as
positive immunoreactivity (Fig. 7a). These patient samples were
analyzed for correlation between RAP1 expression and patient
survival. Importantly, patients with higher RAP1 levels responded
poorly to chemotherapy as their tumors were resistant to death,
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Fig. 5 RAP1 mediates interaction between XRCC4/Lig IV and DNA-PK. a Flag-tagged RAP1 mutants (as indicated) were expressed in cells followed by IP
using anti-Flag beads. The IP eluate was immunoblotted for the indicated proteins. Inputs are shown in bottom panel. b MCF7 cells were transfected with
shcontrol or shRAP1, and left untreated (UT) or treated with CPT (10 μM) for 3 h (represented as 0 time point). Following this, cells were released for
various time points and fractionated and blotted for indicated proteins. WCE indicated whole-cell extract c Co-immunoprecipitation of lysates from shRAP1
or shControl cells UT or treated with CPT (10 μM) for 3 h and released for the indicated times. Immunoblots demonstrate association of indicated proteins.
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progression-free survival (PFS) (Fig. 7b). Indeed, when cells are
treated with CPT, the levels of RAP1 were found to be increased
in nuclear fraction of cells (Supplementary Fig. 4F). To further
strengthen the notion that RAP1 levels could be predictive of
chemotherapy outcome, and to test the generality of our findings,
we evaluated another chemotherapeutic regimen using CPT,
which has been shown to be efficacious in colon cancer treatment.
Indeed, survival analysis on two independent studies42,43 showed
that reduced RAP1 levels predict better survival (Fig. 7c, d).
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recruitment of DNA repair complexes on chromatin upon DSB
induction. A model based on our studies is presented (Fig. 7e).
We suggest that RAP1 expression levels could be used as a
prognostic tool for response to chemotherapy.
Discussion
Here, using mouse models, human cancer cells, and data from
phase II clinical trials, we suggest that mammalian Rap1 is an
important regulator of genome stability in response to genotoxic
and oncogenic signals, and it functions by controlling the
recruitment of Ligase IV to the damaged chromatin due to its
ability to serve as an adaptor. Our results do not exclude the
possibility that Rap1 also functions in pathways that lead to
repair, other than the one elucidated here, especially since it is
clear that its interactome (Supplementary Fig 4A, B) is rich with
DDR protiens. The covalent modifications of Rap1 which ensue
upon specific kinds of damage and allow it to function effectively
as an adaptor need further examination. Indeed Rap1 has context
dependent functions as exemplified by the obesity phenotype
which is seen only in Rap1 null females23,24.
Although mammalian Rap1 is one of the most conserved
proteins, we have only just begun to understand its role, since
unlike yeast Rap1, the mammalian Rap1 cannot bind DNA and
since Rap1 null cells have no telomere defects. Extensive studies
performed by the de Lange and Chang laboratories have shown
that Rap1 is required for the prevention of aberrant Holliday
junction resolution at telomeres by increasing T-loop formation,
and that the loss of Rap1 results in aberrant homologous repair of
the telomeres 9,44. This led us to hypothesize that there must be a
reason for the conservation of this protein. Further, not only
does its levels increase in cancers, additional mutations which
lead to loss of its C terminus in cancers have recently been
described. In this manuscript we provide evidence that mam-
malian Rap1 directly regulates DNA damage signaling, inde-
pendent of its association with the telomeres or with its known
partner TRF2. Several lines of evidence have previously hinted at
the involvement of yeast and mammalian Rap1 in DDR. Firstly,
RAP1 has been found to be phosphorylated in response to IR and
UV in human cells45 and associated with various components of
DDR machinery7. Secondly, RAP1 levels were upregulated upon
DNA damage46. Also, yeast Rap1 was shown to have an impor-
tant role in genome stability47. However, the precise contribution
of mammalian Rap1 in this context was enigmatic. The partici-
pation of DDR and checkpoint activity in tumor suppression is
highly appreciated in the context of oncogene-driven tumor-
igenesis48. The poorer survival of Eμ-Myc mice when Rap1 is null
is much like the phenotype of this oncogene in ATM null
background49, further increasing confidence in the notion that
lack of Rap1 abrogates oncogene-induced DNA repair. Rap1
deficiency led to defects in DNA damage foci resolution, ulti-
mately leading to cell death. This sensitivity to genotoxic stress is
similar to that observed for the various members of the DNA
damage pathway50–52 such as ATM, DNA-PK, Ligase IV, KU,
and ATR. Enzyme-mediated repair of DSBs is a major mechan-
ism of resistance to both ionizing radiation (IR) and drugs that
cause DSBs. Thus, helping cells repair damaged DNA may be one
of the important functions of RAP1 that leads to better cancer cell
survival and worse patient surival. Importantly, this has been
observed in breast cancer patients and colon cancer patients
undergoing chemotherapy (Fig. 7).
The seemingly discordant data between accelerated death and
lymphomagenesis in Eμ-myc-positive mice when Rap1 is null, but
increased human patient survival when RAP1 is low need further
explanation. Notwithstanding the differences between mice and
humans, the major point of difference is that the human patient
cohorts that are described were treated with chemotherapy
(unlike the mice). Low levels of RAP1 lead to reduced repair of
damaged DNA in tumor cells and this causes increased death of
tumors which translates into better patient survival post che-
motherapy. On the contrary, human tumors cells with high RAP1
repair more efficiently the DNA damage caused by chemotherapy
drugs. Due to increased repair, RAP1-high human tumors survive
better. This classical chemoresistance phenotype is well char-
acterized in cancer patients. When tumor cells survive more,
there is poorer patient survival (due to subsequent processes like
metastasis). It is important to note that the increased expression
of most DNA repair genes causes resistance to genotoxic com-
pounds in human cancer. Adriamycin resistance in leukemic/
breast cells is correlated with increased FANCD2 and FANCF
expression53 as well as increased NFκB expression54. Similarly,
since chemoresistant human tumors survive, proliferate, and
metastasize more, RAP1-high patients survive less. This further
reinforces our hypothesis that RAP1 has a non-telomeric function
as an adaptor in the NHEJ pathway, away from the telomeres.
The accelerated lymphomagenesis in mice also fits beautifully
with the known role of DNA damage proteins in the process.
Indeed, the loss of many key DNA damage repair proteins such as
ATM55, MSH2 (ref. 56), and INK4a/ARF57 has been shown to
accelerate Eμ-Myc lymphomagenesis, much like what is seen with
Rap1 loss. Together these results confirm that Rap1 is a bone fide
DNA damage repair protein.
Absence of RAP1 led to reduction in formation of a functional
repair complex due to lack of association of XRCC4/Ligase IV
with DNA-PK leading to impaired recruitment to damaged
chromatin. This observation is important in the context of cancer
or BM failure where efficiency of DDR is the key to cell survival58.
This too is reminiscent of the effect of loss of DDR mediators
such as ATM or the NHEJ complex proteins50,51. We further
mapped the domains of RAP1 required for binding to different
DDR members and found that the CT domain was important for
most of the interactions (Supplementary Fig 4E). However, these
interactions were independent of TRF2 since the RAP1–325
mutant which is unable to bind to TRF2 can efficiently bind to
DNA-PK, Ligase IV, and XRCC4 proteins (Fig. 5a). Indeed,
several human cancer patients have been found to harbor non-
sense or deletion mutations right before CT domain of RAP1
(Supplementary Fig. 5)59,60, which could generate a RAP1 mutant
Fig. 6 Rap1 regulates regulates NHEJ in vivo. a Schematic of cell-based repair assay (adapted from Bennardo et al.)37. b Average percentage of GFP-
positive cells as a readout for NHEJ activity in RAP1 WT and KD cell lines from three independent experiments normalized to average percentage of GFP-
positive cells in the WT cell line (Mean ± SEM) (**p < 0.01) (one-way ANOVA; Turkey’s multiple comparison test) (Scr= scrambled, KD1= shRAP1
construct 1, KD2= shRAP1 construct 2). c Representative FACs analysis of GFP-positive cells (corresponding from left to right: Scr, KD1, and KD2).
d Representative FACs contour plots of B220 and IgG1 doubly stained B cells undergoing in vitro CSR via stimulation with LPS and IL4. Top panel
represents B cells from the respective genotypes stained on D0 (day 0) of CSR; bottom panel represents B cells from the respective genotypes stained on
D3 of CSR. Leftmost panel depicts unstained cell population. e Representative plot of % CSR in WT vs. Rap1 KO B cells of a representative biological
replicate. f Plot of CSR in WT vs. Rap1 KO B cells, normalized to WT B cell CSR, over three independent biological experiments. g Mean ± SD of Averaged
deficiency in CSR between WT vs. Rap1 KO B cells across three independent biological replicates (*p < 0.05) (two-tailed Student’s t-test).
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Fig. 7 RAP1 levels correlate with response to chemotherapy and patient survival. a IHC staining of RAP1 in breast cancer patient tissues. Staining intensity
was classified into four groups: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Staining scores 0 and 1 were grouped as negative immunoreactivity
whereas 2 and 3 were grouped as positive immunoreactivity. Scale bar, 50 μm. b Graphs showing correlation of progression free and overall survival with
RAP1 levels (n= 31). c, d For survival data analysis of colorectal cancers, raw gene expression data with GEO accession numbers of GSE17538 (n= 232)
and GSE39582 (n= 1193) were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo/). Normalization of the raw data was performed
across all samples based on the Cross Correlation method63. Stratification of samples replied on the distribution of RAP1 (TERF2IP) expression intensities
cross all samples. Ten percent below or over the RAP1 median expression value was used as the cutoff for selection of RAP1 lower or higher samples,
respectively. The analysis of the survival data was based on the Kaplan–Meier method. e Model showing that RAP1 binds DDR complex proteins and
regulates their formation and recruitment on chromatin.
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which is unable to interact with these repair proteins and thus
affect disease progression and response to chemotherapy. Taken
together, our data uncover a previously uncharacterized aspect of
RAP1 function in cellular response to DNA damage. This non-
telomeric adaptor role of RAP1 could make RAP1 a good bio-
marker and therapeutic target in chemotherapeutics for human
cancer.
Methods
Cells and reagents. Rap1 WT and KO MEFs were derived by timed mating of
Rap1+/− (Rap1 heterozygous) mice. Briefly, embryos were harvested at E13.5,
internal organs removed, and fibroblasts cultured in Dulbecco’s modified eagle
medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 2 mM sodium pyruvate, 2% β-mercaptoethanol, and 1×
PSF (penicillin, streptomycin, and fungizone) at 37 °C with 10% CO2. MCF7 cells
(ATCC® HTB-22™) and 293T (ATCC® CRL-3216™) were grown in DMEM; all
media were supplemented with 10% FBS, 2 mM L-glutamine, 2 mM sodium pyr-
uvate, and 1× PSF at 37 °C with 5% CO2. Antibodies against CHK2 (Cell Signaling
Technology: #2662), pCHK2 (Cell Signaling Technology: #2661), ATM (Cell Sig-
naling Technology: #2873 S), and KU80 (Cell Signaling Technology: #2180) were
from Cell Signaling Technology. Rap1 (Santa Cruz: sc-53434 and sc-28197) was
from Santa Cruz Biotechnology, TRF2 (Millipore: #05–521) and pATM (Millipore:
#05–740) antibody were from Millipore. Ligase IV (Proteintech: #12695-1-AP)
antibody was from Proteintech. XRCC4 (ab145) and DNA-PK (ab1832) antibodies
were from Abcam and used at 1:2000 dilutions. All other antibodies were used at
1:1000 dilutions. Primers used in this study are listed in Supplementary Table 1.
Transfection of plasmids and siRNA. Plasmids-overexpressing Flag-RAP1 was
generated by cloning RAP1 ORF into pBOBi lentiviral plasmid. shRAP1 was
generated by cloning target sequence into pLKO vector (sequence can be obtained
upon request). RAP1 deletion mutants were a gift from Titia de Lange6. Linker
scanning mutations in RAP1 CT domain were generated as described before61 and
the mutants were cloned into Flag-tagged pBOBi. Lentiviruses were generated as
described previously22. siRNA against RAP1 was obtained from Qiagen or Dhar-
macon. Control siRNA was from Qiagen. Cells were transfected using either
Lipofectamine LTX or Lipofectamine RNAiMax for 48–72 h according to the
manufacturer’s instructions.
Cell death assay. Cells were plated 7 × 104 per well of a 12-well plate in duplicates
for 24 h. They were treated with Dox or CPT for 24 and 48 h. Thereafter, all cells in
the supernatant as well as adherent cells were collected from each well and
resuspended in an equal volume of phosphate-buffered saline (PBS). Equal volume
of trypan blue dye was added to each sample. Total number of cells and dead cells
were then counted using a hemocytometer. Cell death is presented as the per-
centage of dead cells compared to total cells in each well.
Western blot analysis. Total protein was extracted with Totex buffer (20 mM
Hepes at pH 7.9, 0.35 M NaCl, 20% glycerol, 1% NP-40, 1 mM MgCl2, 0.5 mM
EDTA, 0.1 mM EGTA, 50 mM NaF, and 0.3 mM NaVO3) containing a mixture of
protease inhibitors (Roche). Proteins were separated on NuPAGE Novex 4–12%
Bis-Tris gels (Invitrogen) followed by immunoblotting with specific antibodies and
detection using ECL Western blotting detection kit (Amersham Bioscience).
Co-immunoprecipitation. Cells were washed with ice-cold PBS and then lysed in
IP buffer (10 mM Tris at pH 8, 170 mM NaCl, 0.5% NP-40, and protease inhibi-
tors) for 30 min on ice. Cell lysates were removed by centrifugation and the
supernatants were incubated with Flag M2 antibody beads (sigma) or other anti-
bodies as indicated overnight at 4 °C. Flag beads were washed four times with 1 ml
of wash buffer (containing 200 mM Tris at pH 8.0, 100 mM NaCl, and 0.5% NP-
40). For other antibodies, protein G sepharose beads were added for 2 h, rotated at
4 °C, and washed as flag beads. Bound proteins were eluted with 3X-Flag peptide or
SDS sample buffer and subjected to western blot analysis.
Cellular fractionation. The cells were harvested in ice-cold PBS and resuspended
in hypotonic lysis buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl,
protease, and phosphatase inhibitors) and incubated on ice for 4 min. They were
then spun down for 3 min at 1902 × g and the cytoplasmic fraction aspirated to
separate tubes. The pellet was washed with hypotonic buffer once. The soluble
nuclear fraction was then lysed in IP buffer on ice for 10 min. The lysate was
clarified by centrifugation at 9391 × g for 10 min at 4 °C. For chromatin-bound
fraction, pellet was resuspended in IP buffer and sonicated in Bioruptor with 30 s
on/off cycle for 7 min. Clarified extract was used as chromatin fraction. Fractions
were then analyzed using western blotting.
NHEJ DSB repair assay. DSB repair assay was performed as described by Ben-
nardo and colleagues. Using MCF7 RAP1 knockdown cell lines (KD1 and KD2)
and control cell line (Scr), 1 × 106 cells were seeded into six-well plates. The cells
were transfected with pCBASceI and pimEJ5GFP using X-tremeGENE™ 9 DNA
Transfection Reagent (6365779001) the following day with the manufacturer’s
protocol. The NHEJ DSB assay was performed 3 days after the transfection. The
cells were harvested and washed with PBS, and resuspended in 10% FBS in PBS.
The cells were put through the flow cytometric analyzer and 10,000 events were
recorded for each sample. The results were analyzed using FlowJo.
Comet assay. Comet assay was performed using CometAssay® Kit (25 × 2 well
slides) from Trevigen (4250–050-K) following the manufacturer’s protocol with slight
modifications. Rap1 WT and KO MEFs were seeded in six-well plates (0.2 × 106 cells
per well). The cells were treated with 10 μM of CPT for 3 h before harvesting. The cell
pellets were resuspended in 200 μL of cold PBS. One hundred and twenty microliters
of 0.75% agarose was added to 10 μL of cells (0.01 × 106 cells) and pipetted onto the
microscopic slides. The gel was allowed to set at 4 °C for 30min. The remaining steps
were performed following the manufacturer’s protocol and the slides were imaged
using the Zeiss LSM 800 and quantitated using ImageJ.
Mice. Rap1 KO mice on a mixed background were generated as described in the
text. Briefly, Rap1 conditional knockout mice were crossed to β-actin-Cre trans-
genic mice to generate whole-body Rap1 knockout mice (KO, Rap1−/−). These
mice were subsequently backcrossed six to seven times with C57BL6 mice to
generate at least a 99.2–99.6% contribution of C57BL6, and used for the gamma
irradiation, 5-FU and MEF experiments. These Rap1−/− mice were also crossed to
Eμ-Myc transgenic mice on a C57BL6 background30 to generate Eμ-Myc Rap1+/−
mice. Eμ-Myc Rap1+/− and Rap1+/− F1 mice were intercrossed to produce Eμ-
Myc Rap1+/+, Eμ-Myc Rap1+/−, Eμ-Myc Rap1−/−, Rap1+/+, Rap1+/−, and
Rap1−/− offsprings. Eμ-Myc-positive littermates were monitored over the course of
their disease and used for subsequent experiments. Rap1 KO PyMT mice were
generated by crossing Rap1−/− mice with MMTV-PyMT mice (Jackson Labora-
tory). Animal experiments were approved by the Agency for Science, Technology
and Research’s Biological Resource Centre Institutional Animal Care and Use
Committee (Rap1+/+ denotes Rap1 wild-type mice, Rap1+/− denotes Rap1 het-
erozygous mice, Rap1−/− denotes Rap1 knockout mice.)
Class switch recombination assays. Rap1−/− mice have been backcrossed for at
least nine generations with C57BL6 mice to generate 99.9% contribution of
C57BL6, before they were used for the class switch recombination assays. Briefly,
splenic B cells were purified from the spleens of WT or Rap1 KO mice using anti-
CD43 magnetic beads. The B cells were stimulated for 72 h with 10 μg/ml LPS
(Sigma) and 10 ng/ml IL-4 (R&D Systems) in RPMI media to induce IgG1 class
switch recombination. B cells were harvested at the stipulated time points, washed
with PBS, and stained with anti-B220 (BD Biosciences, 553092) and anti-IgG1 (BD
Biosciences, 553441) antibodies and analyzed via flow cytometry.
Analysis of peripheral blood cells. Peripheral blood (PB) was collected by retro-
orbital bleeding and complete blood counts were performed using an automated
hemocytometer, Hemavet (Drew Scientific).
Isolation of BM cells. BM cells were flushed from the long bones (tibias and
femurs) with minimum essential medium alpha medium (α-MEM) (Gibco) sup-
plemented with 10% heat-inactivated FBS (Gibco). Cells were filtered through
nylon filter (35 μm) to obtain a single-cell suspension.
Flow cytometric analysis and cell sorting. For flow cytometric analysis, BM cells
were preincubated with mouse serum for 15 min on ice before staining. The
antibody reaction was carried out in the mouse serum for additional 20 min on ice.
After addition of 0.5 μg/ml of Hoechst 33258 pentahydrate to exclude dead cells,
analysis was performed using a LSR II flow cytometer (BD Biosciences) and
analyzed using the FlowJo software (Tree Star). Sorting of KSL cells were per-
formed using FACSAria (BD Bioscience).
For analysis and sorting of myeloid progenitors and HSPCs, cells were stained
with antibodies against c-Kit (PE-Cy7), Sca-1 (APC), and lineage markers (PE)
including CD3, CD4, CD8, B220, Gr-1, Mac-1, Ter117, and IL7Rα. Mature cells
were identified as follows: myeloid, Mac1+ (Mac1 positive) and Gr1+; B cells,
B220+ CD19+; erythroid cells, Ter119+; T cells CD4+ and CD8+. Antibodies were
purchased from e-Bioscience and BD Pharmingen (San Diego).
For intracellular γ-H2AX staining, KL-sorted cells were first incubated in fixable
viability dye-eFluor 780 (eBioscience) before fixation in 1% PFA on ice. The cells
were then permeabilized with 0.25% Triton-X in 1% bovine serum albumin (BSA)-
PBS on ice. Subsequently, cells were incubated with γ-H2AX antibody (Cell
Signaling Technology) in 10% goat serum in 1% BSA-PBS and finally incubated
with secondary antibody conjugated with Alexa Fluor 647.
Cell cycle and apoptosis assay. For Annexin V apoptosis assay, stained cells were
suspended in final buffer containing Annexin V antibody and Hoechst 33258 dye.
All antibodies were purchased from BD Pharmingen (San Diego, CA, USA). For
cell cycle analysis, cKIT-positive cells were sorted on a Becton Dickinson FACSAria
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II cell sorter (BD Biosciences), fixed in ice-cold 70% ethanol, and then treated with
1 mg/ml of RNAse A and stained with 500 μg/ml PI staining solution.
Flow cytometric analysis of lymphoid development. Hematopoietic stem and
progenitor cell and lineage-positive cell profiling was perform on BM, spleen, and
thymus of mice from each genotype. Antibodies (clones) used: CD3 (145-2C11)
[BD: #553064], CD4 (H129.19) [BD: #553653], CD8 (53-6.7) [BD: #553033], Gr-1
(RB6-8C5) [BD: #553128], B220 (RA3-6B2) [BD: #553090], Ter119 (Ter119) [BD:
#553673], Mac1 (M1/70) [BD: #553311], IL7Rα (A7R34) [eBiosceinces: #12-1271-
82], cKit (2B8) [BD: #558163], Sca-1 (E13-161.7) [eBiosceinces: #17-5981-83],
CD25 (7D4) [eBiosciences: 13-0252-82], CD44 (IM7) [BD: 559250], CD43 (S7)
[BD: 561856], HSA (M1/69) [BD: #553262] and BP-1 (6C3) [BD: #553159], CD4
(GK1.5) [BD: #561830], CD8 (7D4) [eBiosciences: #12-0081-82], B220 (RA3-6B2)
[BD: #561880].
Flow cytometric gating strategy is described in Supplementary Fig. 6.
Immunofluorescence staining. Sorted cells were collected onto glass slide using
Cytospin4 cytocentrifuge (Fisher Scientific) and fixed using 4% PFA before per-
meabilized with 0.3% Triton X-PBS. All wash steps were carried out using 0.1%
NP-40 in PBS (washing buffer). Slides were blocked overnight at 4 °C with 10%
goat serum in washing buffer. Staining was carried out by incubating cells with
anti-γ-H2AX antibody (Millipore: 05–636) and anti-53BP1 antibody (Cell Sig-
naling Technology: #4937 S) further incubated with Alexa Fluor 488 and 647-
conjugated secondary antibodies. Slides were then visualized on the A1 Confocal
microscope system (Nikon). For γ-H2AX-TTAGGG-PNA probe co-staining, cells
were fixed in 4% formaldehyde for 15 min, permeabilized with 0.2% (v/v) Triton-X
at 4.0 °C for 10 min, and blocked with 0.5% BSA for 30 min. Primary antibody
incubation with anti-γ-H2AX for 1 h was followed by three washes before incu-
bation with secondary anti-rabbit antibody. Slides were then fixed in 4% for-
maldehyde to cross-fix antibodies before hybridization with telomeric PNA. For
more details, please refer to Yasaei et al.62.
CFU-C assay. In all, 50,000 sorted cKit+Lin− cells were seeded in 35-mm dishes in
either duplicates or triplicates in Methocult M3231 methylcellulose medium
(StemCell Tec., Vancouver, BC, Canada) containing 1% antibiotic–antimycotic
supplemented with 10 ng/ml recombinant murine IL-3, 10 ng/ml SCF, 10 ng/ml G-
CSF, and 10 ng/ml EPO. Cells were incubated at 37 °C, 5% CO2. Colony formation
was scored with an inverted microscope after 7 days of culture. Colonies consisting
of more than 20 cells were scored. For serial replating assays, colonies were har-
vested in cold PBS, centrifuged at 440 × g for 5 min to collect cell pellet and colony
assay was repeated using 50,000 cells for the next round.
γ-Irradiation, 5-FU treatment, and Kaplan–Meier curve. Rap1WT, KO, and Het
age-matched mouse cohorts (8–12 weeks old males, n= 5) were irradiated with 11
Gy and survival was monitored twice daily. 5-FU was dissolved in water and
150 mg/kg was injected intraperitoneally and mice were monitored for death.
Readings were plotted in prism software and the Kaplan–Meier survival curve was
plotted.
Breast cancer patient samples. Patients Study Cohort: TMA blocks containing
serial tumor cores from the 100 patients were constructed where four core biopsies
from each patient were obtained: at baseline, 3 weeks after the first and second cycles
of chemotherapy, and upon completion of six cycles of chemotherapy or at study
withdrawal41. The cases were given randomized alternating sequences of doxorubicin
(A) and docetaxel (T), starting either with doxorubicin 75mg/m2 or docetaxel
75mg/m2 every 3 weeks for six cycles. PFS and OS were defined as the time between
the date of randomization and the first documented evidence of progression, and the
time between the date of randomization and death, respectively.
Scoring of RAP1 expression. The nuclear immunostaining of RAP1 was graded
according to the intensity of positive staining in cancer cells. Staining intensity was
classified into 4 groups: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong).
Staining scores 0 and 1 were grouped as negative immunoreactivity whereas 2 and
3 were grouped as positive immunoreactivity.
Statistical analysis. Univariate and multivariate Cox proportional hazards models
were carried out with PFS or OS as the end point. Survival analysis was conducted
using Kaplan–Meier and the log-rank test was employed to determine the differ-
ence. All statistical analysis were performed using the SPSS package (version 18.0
for Windows; SPSS Inc., USA) with significance set at the 5% level.
Colorectal cancer patient samples. Raw gene expression data with GEO accession
numbers of GSE17538 (ref. 42) and GSE39582 (ref. 43) were downloaded from the
GEO database (http://www.ncbi.nlm.nih.gov/geo/). In GSE39582 a total of 1193
colorectal cases were studied, and among Stage II–III cases, 418 cases received
adjuvant chemotherapy of fluorouracil and folinic acid. In GSE17538 a total of 232
cases were studied.
Gel filtration. Briefly, cells were harvested and resuspended in gel filtration buffer
(20 mM Tris pH 7.5, 100 mM NaCl, 10 mM b-glycerol, 1 mM Benzamidine, 25 mM
NaF, 1 mM DTT, 0.33 mM NaVO4) supplemented with protease and phosphatase
inhibitors. Cells were sonicated and centrifuged for 15 min at 18407 × g. The
supernatant was collected and filtered through at 0.22 μm filter before quantitation.
The sample was then transferred into a 5 ml syringe for loading into the gel
filtration system. For more details, please refer to Wu et al34.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data Availability
All data needed for interpretation of the results are presented in this paper; original
source of big data sets are quoted in the Methods section. Source data underlying
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